No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Agilent Technologies, Inc. is a global enterprise that develops and delivers specialized solutions primarily for the life sciences, diagnostics, and applied chemical industries. Within its Life Sciences and Applied Markets division, the company supplies a wide array of laboratory instrumentation. This includes diverse chromatography and mass spectrometry systems (such as liquid, gas, LC-MS, GC-MS, and ICP-MS), along with other analytical instruments like atomic absorption, microwave plasma-atomic emission, ICP-OES, and Raman spectroscopy. For cell analysis, Agilent provides plate-based assays, flow cytometers, real-time analyzers, imaging systems, and microplate readers. The segment also covers comprehensive laboratory software for information management and analytics, automated and robotic lab systems, dissolution testing solutions, vacuum pumps, and specialized measurement technologies. Its Diagnostics and Genomics segment focuses on genetic and diagnostic tools. It offers arrays crucial for various genetic analyses, such as DNA mutation detection, genotyping, gene copy number assessment, identification of gene rearrangements, DNA methylation profiling, gene expression analysis, and target enrichment for next-generation sequencing. This segment also delivers genetic data management and interpretation software, alongside producing synthesized oligonucleotides. Furthermore, it supplies immunohistochemistry, in situ hybridization, and H&E (hematoxylin and eosin) and special staining products. Consumables and software for nucleic acid sample quality control, reagents for turbidimetry and flow cytometry, and the development of liquid-based pharmacodiagnostics are also part of its portfolio. The Agilent CrossLab segment is dedicated to providing essential laboratory consumables, including GC and LC columns, sample preparation products, custom chemistries, and general instrument supplies. Additionally, it offers a comprehensive suite of services, encompassing startup support, operational assistance, training, compliance support, software-as-a-service (SaaS) solutions, asset management, and expert consultation. Agilent distributes its products through multiple channels, including direct sales, various distributors, resellers, manufacturer's representatives, and e-commerce platforms. Established in 1999, Agilent Technologies, Inc. maintains its corporate headquarters in Santa Clara, California.
www.agilent.comNo one on the platform currently holds 0HAV.L.
No tracked institution reports a position in 0HAV.L as of their last filing.
No one on the platform has traded 0HAV.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.0% | 15.1% | 14.5% | — | — | — |
| Rev. Growth % | -71.4% | -19.0% | ||||
| Profit Margin % | 23.3% | 19.7% | 16.6% | |||
| Free Cash Flow Margin % | 61.9% | 28.0% | 22.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $7.5B | +8.4% | $6.20 | $6.14–$6.25 | — | 1 |
| 2027 | $8.0B | +6.5% | $6.74 | $6.68–$6.79 | — | 1 |
| 2028 | $8.5B | +6.5% | $7.47 | $7.40–$7.53 | — | 1 |
| 2029 | $9.1B | +6.8% | $8.26 | $8.18–$8.31 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-26 | $1.49 | $1.62 | +8.7% |
| 2026-05-27 | $1.41 | $1.49 | +5.7% |
| 2026-02-25 | $1.37 | $1.36 | -0.7% |
| 2025-11-24 | $1.58 | $-1.53 | -196.9% |
| 2025-08-27 | $1.37 | $1.18 | -13.9% |
| 2025-05-28 | $1.26 | $1.31 | +4.0% |
| 2025-02-25 | $1.28 | $1.11 | -13.3% |
| 2024-11-26 | $1.41 |
| $1.22 |
| -13.5% |
| +1.41% |
| $27.6B |
| — |
| 0JDM.LIQVIA Holdings Inc. | $263.84 | -0.72% | $44.5B | — |
| 0K10.LMettler-Toledo International Inc. | $1276.88 | -0.45% | $26.0B | — |
Source: Financial Modeling Prep · peers by sector/industry